Pharm-Olam is marking its 25th anniversary with several announcements and a rebrand. The company has changed its name from Pharm-Olam International to Pharm-Olam to match its global services and positioning.
The clinical development solutions CRO offers services for oncology-haematology, infectious diseases, vaccines, and rare diseases. 25 years on from its founding, the company is still striving to improve these offerings, making announcements of milestones and updates to its operations.
These updates include:
- An upgrade to its rare disease service tier.
- Progress on its transition to the Medidata Cloud platform.
- Ongoing global expansion.
Rare disease service
To provide increased support to sponsors, Texas-based Pharm-Olam is enhancing its rare disease services and elevating it to their Center of Excellence (COE) tier, thus joining oncology-haematology as well as infectious disease and vaccines in this category. This service tier offers sponsors dedicated staff, enhanced technology, optimised processes, and site and vendor partners to meet the unique demands and challenges.
Pavle Vukojevic, Chief Medical Officer at Pharm-Olam, said: “We have completed over 100 rare disease clinical trials covering more than 30 indications, which have led to multiple drug marketing authorisations by the FDA, EMA, and other regulatory bodies worldwide. This area of research continues to see increased industry investment and public awareness, and we will continue to invest and support our sponsors where they need us most.”
Medidata cloud platform
To further bolster its clinical trial execution, Pharm-Olam and Medidata previously announced an expansion of their relationship with a unique partnership to utilise the full power of Medidata’s Cloud. In total, Pharm-Olam will deploy over 15 Medidata products, and its sponsors will benefit from cross-communication, data sharing between systems, and study-portfolio level analytics, thus providing a comprehensive solution for deeper study insights and evidence-based decision making.
Global expansion
Additionally, Pharm-Olam cites its increased global reach, covering 65 countries, as a key competitive advantage enabling the company to deliver clinical trials around the world.
In 2018, the company added operations in Australia, South Korea, Malaysia, Philippines, and Thailand and will further expand in 2019.
